Skip to main content

hpv16 e6/7 mrna vaccine bnt113

Generic: HPV16 E6/7 mRNA Vaccine BNT113

hpv16 e6/7 mrna vaccine bnt113: 2 clinical trials tracked.

hpv16 e6/7 mrna vaccine bnt113 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hpv16 e6/7 mrna vaccine bnt113, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trial Registry Records (2)

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

NCT04534205Registry updated 2026-09-21·Phase 2/Phase 3·BNTX
Active, not recruiting

Primary endpoint: Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab

InterventionalRandomizedopen358 enrolledStarted 2021-01Completion 2028-0850 sites · Argentina, Australia, Austria, Belgium…BioNTech SE

Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

NCT03418480Registry updated 2026-10-07·Phase 1/Phase 2
Completed

Primary endpoint: Dose Limiting Toxicity (DLT) according to CTCAE version 4.03 (Arm 1A and Arm 1B)

Interventionalopen30 enrolledStarted 2017-04Completion 2024-012 sites · United KingdomUniversity of Southampton